Request Demo-Call
Request Demo-Call
Transforming Cardiovascular Care Through AI
Transforming Cardiovascular Care Through AI
Transforming Cardiovascular Care Through AI
Request INVESTMENT DECK
Request INVESTMENT DECK
Seed Round Investment Opportunity
Seed Round Investment Opportunity
$5,000,000
$5,000,000
$183B
$183B
Market Size
(2030)
8
8
Specialized
AI Agents
Specialized
AI Agents
5
5
Risk
Calculators
Risk
Calculators
24/7
IoMT
Monitoring
Confidential Investment Memorandum December 2025
For Qualified Investors Only
Confidential Investment Memorandum December 2025
For Qualified Investors Only
Confidential Investment Memorandum December 2025
For Qualified Investors Only
Investment Opportunity:
Investment Opportunity:
Cardio AI is revolutionizing cardiovascular medicine through a unified multi-agent AI system that
combines cutting-edge risk prediction, real-time patient monitoring, and personalized care
recommendations. Our platform addresses the $183B cardiovascular care market with innovative
technology that reduces hospitalizations by 30%, improves outcomes by 25%, and decreases
healthcare costs by up to 40%.
Cardio AI is revolutionizing cardiovascular medicine through a unified multi-agent AI system that
combines cutting-edge risk prediction, real-time patient monitoring, and personalized care
recommendations. Our platform addresses the $183B cardiovascular care market with innovative
technology that reduces hospitalizations by 30%, improves outcomes by 25%, and decreases
healthcare costs by up to 40%.
Investment Highlights
Investment Highlights
✓ FDA breakthrough device designation pathway
✓ FDA breakthrough device designation pathway
✓ Strategic partnerships with 3 major health systems
✓ Strategic partnerships with 3 major health systems
✓ Validated risk models with AUC >0.82 across all calculators
✓ Validated risk models with AUC >0.82 across all calculators
✓ 18-month runway to commercialization
✓ 18-month runway to commercialization
✓ Experienced founding team from Stanford, Mayo Clinic, Google Health
✓ Experienced founding team from Stanford, Mayo Clinic, Google Health
Our Technology Platform
Our Technology Platform
Component
Component
Unified Multi-Agent System
Unified Multi-Agent System
5 Risk Calculators
5 Risk Calculators
IoMT-RPM Integration
IoMT-RPM Integration
Three-Tier Confidence
Framework
Three-Tier Confidence
Framework
8 Specialized AI Agents
8 Specialized AI Agents
Description
Description
8 specialized AI agents delivering comprehensive cardiovascular care management and clinical decision support
8 specialized AI agents delivering comprehensive cardiovascular care management and clinical decision support
8 specialized AI agents delivering comprehensive cardiovascular care management and clinical decision support
8 specialized AI agents delivering comprehensive cardiovascular care management and clinical decision support
Deep learning models for AMI, Heart Failure, Stroke, Sudden Cardiac Death, and Atrial Fibrillation (AUC >0.82)
Deep learning models for AMI, Heart Failure, Stroke, Sudden Cardiac Death, and Atrial Fibrillation (AUC >0.82)
Deep learning models for AMI, Heart Failure, Stroke, Sudden Cardiac Death, and Atrial Fibrillation (AUC >0.82)
Deep learning models for AMI, Heart Failure, Stroke, Sudden Cardiac Death, and Atrial Fibrillation (AUC >0.82)
Real-time monitoring through wearables and medical devices, processing 1M+ data points daily
Real-time monitoring through wearables and medical devices, processing 1M+ data points daily
Real-time monitoring through wearables and medical devices, processing 1M+ data points daily
Real-time monitoring through wearables and medical devices, processing 1M+ data points daily
Proprietary oversight ensuring clinical safety while maximizing AI autonomy for time-critical decisions
Proprietary oversight ensuring clinical safety while maximizing AI autonomy for time-critical decisions
Proprietary oversight ensuring clinical safety while maximizing AI autonomy for time-critical decisions
Proprietary oversight ensuring clinical safety while maximizing AI autonomy for time-critical decisions
Risk Assessment | Diagnostic Support | Treatment Planning | Patient
Monitoring | Alert Management | Patient Engagement | Documentation | Research & Analytics
Risk Assessment | Diagnostic Support | Treatment Planning | Patient
Monitoring | Alert Management | Patient Engagement | Documentation | Research & Analytics
Risk Assessment | Diagnostic Support | Treatment Planning | Patient
Monitoring | Alert Management | Patient Engagement | Documentation | Research & Analytics
Risk Assessment | Diagnostic Support | Treatment Planning | Patient
Monitoring | Alert Management | Patient Engagement | Documentation | Research & Analytics
Massive Market Opportunity
Massive Market Opportunity
Market Metric
Market Metric
Global CV Care Market by 2030
Global CV Care Market by 2030
Global CV Care Market by 2030
Global CV Care Market by 2030
People with CVD Worldwide
People with CVD Worldwide
People with CVD Worldwide
People with CVD Worldwide
CAGR for AI in Healthcare
CAGR for AI in Healthcare
CAGR for AI in Healthcare
CAGR for AI in Healthcare
Remote Patient Monitoring Market
Remote Patient Monitoring Market
Remote Patient Monitoring Market
Remote Patient Monitoring Market
AI Clinical Decision Support
AI Clinical Decision Support
AI Clinical Decision Support
AI Clinical Decision Support
Cardiovascular Diagnostics
Cardiovascular Diagnostics
Cardiovascular Diagnostics
Cardiovascular Diagnostics
Value
Value
$183 Billion
$183 Billion
$183 Billion
$183 Billion
659 Million
659 Million
659 Million
659 Million
32%
32%
32%
32%
$3.8B (2024)
$3.8B (2024)
$3.8B (2024)
$3.8B (2024)
$1.9B (2024)
$1.9B (2024)
$1.9B (2024)
$1.9B (2024)
$8.2B (2024)
$8.2B (2024)
$8.2B (2024)
$8.2B (2024)
Use of Funds ($5M Seed Round)
Use of Funds ($5M Seed Round)
Allocation
Allocation
Clinical Validation Studies
Clinical Validation Studies
Clinical Validation Studies
FDA Regulatory Submission
FDA Regulatory Submission
FDA Regulatory Submission
Product Development &
Engineering
Product Development &
Engineering
Product Development &
Engineering
Market Development &
Operations
Market Development &
Operations
Market Development &
Operations
Amount
Amount
$2,000,000 (40%)
$2,000,000 (40%)
$2,000,000 (40%)
$1,500,000 (30%)
$1,500,000 (30%)
$1,500,000 (30%)
$1,000,000 (20%)
$1,000,000 (20%)
$1,000,000 (20%)
$500,000 (10%)
$500,000 (10%)
$500,000 (10%)
Purpose
Purpose
Multi-center prospective trials, external validation, peer-reviewed publications
Multi-center prospective trials, external validation, peer-reviewed publications
Multi-center prospective trials, external validation, peer-reviewed publications
Multi-center prospective trials, external validation, peer-reviewed publications
510(k) pathway, quality management system,
regulatory consulting
510(k) pathway, quality management system,
regulatory consulting
510(k) pathway, quality management system,
regulatory consulting
510(k) pathway, quality management system,
regulatory consulting
Platform enhancement, IoMT integration, security
infrastructure
Platform enhancement, IoMT integration, security
infrastructure
Platform enhancement, IoMT integration, security
infrastructure
Platform enhancement, IoMT integration, security
infrastructure
Partnership development, pilot deployments, team
expansion
Partnership development, pilot deployments, team
expansion
Partnership development, pilot deployments, team
expansion
Partnership development, pilot deployments, team
expansion
18-Month Commercialization Roadmap
18-Month Commercialization Roadmap
Timeline
Timeline
Q1 2026 (Months 1-3)
Q1 2026 (Months 1-3)
Q2-Q3 2026 (Months 4-9)
Q2-Q3 2026 (Months 4-9)
Q4 2026 (Months 10-12)
Q4 2026 (Months 10-12)
Q1-Q2 2027 (Months 13-18)
Q1-Q2 2027 (Months 13-18)
Key Milestones
Key Milestones
• Complete seed funding
• Initiate 3-site clinical validation (n=5,000)
• FDA pre-submission meeting request
• Expand to 12 FTEs
• Complete seed funding
• Initiate 3-site clinical validation (n=5,000)
• FDA pre-submission meeting request
• Expand to 12 FTEs
• Complete seed funding
• Initiate 3-site clinical validation (n=5,000)
• FDA pre-submission meeting request
• Expand to 12 FTEs
• Complete seed funding
• Initiate 3-site clinical validation (n=5,000)
• FDA pre-submission meeting request
• Expand to 12 FTEs
• Clinical validation interim analysis
• FDA pre-submission meeting
• ISO 13485 QMS implementation
• Launch pilot with 2 health systems
• Clinical validation interim analysis
• FDA pre-submission meeting
• ISO 13485 QMS implementation
• Launch pilot with 2 health systems
• Clinical validation interim analysis
• FDA pre-submission meeting
• ISO 13485 QMS implementation
• Launch pilot with 2 health systems
• Clinical validation interim analysis
• FDA pre-submission meeting
• ISO 13485 QMS implementation
• Launch pilot with 2 health systems
• Complete clinical validation
• Submit FDA 510(k) application
• Publish validation results
• Scale to 10 sites, 50K patients
• Complete clinical validation
• Submit FDA 510(k) application
• Publish validation results
• Scale to 10 sites, 50K patients
• Complete clinical validation
• Submit FDA 510(k) application
• Publish validation results
• Scale to 10 sites, 50K patients
• Complete clinical validation
• Submit FDA 510(k) application
• Publish validation results
• Scale to 10 sites, 50K patients
• FDA clearance obtained
• Commercial launch (5 anchor customers)
• Series A fundraising ($20M)
• 100K monitored patients milestone
• FDA clearance obtained
• Commercial launch (5 anchor customers)
• Series A fundraising ($20M)
• 100K monitored patients milestone
• FDA clearance obtained
• Commercial launch (5 anchor customers)
• Series A fundraising ($20M)
• 100K monitored patients milestone
• FDA clearance obtained
• Commercial launch (5 anchor customers)
• Series A fundraising ($20M)
• 100K monitored patients milestone
Competitive Advantages
Competitive Advantages
Advantage
Advantage
Superior Accuracy
Superior Accuracy
Superior Accuracy
Unified Platform
Unified Platform
Unified Platform
Real-Time Processing
Real-Time Processing
Real-Time Processing
Clinical Safety
Clinical Safety
Clinical Safety
Proven Team
Proven Team
Proven Team
Scalable Economics
Scalable Economics
Scalable Economics
Impact
Impact
Risk models outperform existing solutions by 15-20% (AUC 0.82-0.87 vs 0.70-0.75)
Risk models outperform existing solutions by 15-20% (AUC 0.82-0.87 vs 0.70-0.75)
Risk models outperform existing solutions by 15-20% (AUC 0.82-0.87 vs 0.70-0.75)
Risk models outperform existing solutions by 15-20% (AUC 0.82-0.87 vs 0.70-0.75)
Only solution integrating prediction, monitoring, and care coordination in single platform
Only solution integrating prediction, monitoring, and care coordination in single platform
Only solution integrating prediction, monitoring, and care coordination in single platform
Only solution integrating prediction, monitoring, and care coordination in single platform
IoMT integration enables continuous monitoring with 15-day advance warning for cardiac events
IoMT integration enables continuous monitoring with 15-day advance warning for cardiac events
IoMT integration enables continuous monitoring with 15-day advance warning for cardiac events
IoMT integration enables continuous monitoring with 15-day advance warning for cardiac events
Proprietary three-tier oversight framework ensures patient safety and regulatory compliance
Proprietary three-tier oversight framework ensures patient safety and regulatory compliance
Proprietary three-tier oversight framework ensures patient safety and regulatory compliance
Proprietary three-tier oversight framework ensures patient safety and regulatory compliance
Leadership from Stanford, Mayo Clinic, Google Health with 80+ years combined experience
Leadership from Stanford, Mayo Clinic, Google Health with 80+ years combined experience
Leadership from Stanford, Mayo Clinic, Google Health with 80+ years combined experience
Leadership from Stanford, Mayo Clinic, Google Health with 80+ years combined experience
SaaS model with 85% gross margins, rapid deployment, and strong unit economics
SaaS model with 85% gross margins, rapid deployment, and strong unit economics
SaaS model with 85% gross margins, rapid deployment, and strong unit economics
SaaS model with 85% gross margins, rapid deployment, and strong unit economics
Financial Projections
Metric
Monitored Patients
Monitored Patients
Monitored Patients
Revenue (PMPM $40)
Revenue (PMPM $40)
Revenue (PMPM $40)
Gross Margin
Gross Margin
Gross Margin
EBITDA
EBITDA
EBITDA
Year 1
50,000
50,000
50,000
$24M
$24M
$24M
75%
75%
75%
$12M
$12M
$12M
Year 2
250,000
250,000
250,000
$120M
$120M
$120M
82%
82%
82%
$24M
$24M
$24M
Year 3
1,000,000
1,000,000
1,000,000
$480M
$480M
$480M
85%
85%
85%
$168M
$168M
$168M
Revenue Model: Per-member-per-month (PMPM) pricing at $40 for comprehensive cardiovascular care management. Average contract value: $480K annually per 1,000 members.
Revenue Model: Per-member-per-month (PMPM) pricing at $40 for comprehensive cardiovascular care management. Average contract value: $480K annually per 1,000 members.
Current Traction
Current Traction
Category
Category
Strategic Partnerships
Strategic Partnerships
Strategic Partnerships
Technical Milestones
Technical Milestones
Technical Milestones
Achievements
Achievements
• MOU with 3 major health systems (18M lives)
• Partnership with leading wearables manufacturer
• Academic Collaborations: Stanford Medicine,Weill Cornell Medicine, Harvard Medicine
• Advisory board: 8 prominent cardiologists
• MOU with 3 major health systems (18M lives)
• Partnership with leading wearables manufacturer
• Academic Collaborations: Stanford Medicine,Weill Cornell Medicine, Harvard Medicine
• Advisory board: 8 prominent cardiologists
• MOU with 3 major health systems (18M lives)
• Partnership with leading wearables manufacturer
• Academic Collaborations: Stanford Medicine,Weill Cornell Medicine, Harvard Medicine
• Advisory board: 8 prominent cardiologists
• MOU with 3 major health systems (18M lives)
• Partnership with leading wearables manufacturer
• Academic Collaborations: Stanford Medicine,Weill Cornell Medicine, Harvard Medicine
• Advisory board: 8 prominent cardiologists
• Platform MVP complete and tested
• Risk models validated (retrospective n=50,000)
• IoMT integration with 12+ device types
• HIPAA compliance and SOC 2 Type II certified
• Platform MVP complete and tested
• Risk models validated (retrospective n=50,000)
• IoMT integration with 12+ device types
• HIPAA compliance and SOC 2 Type II certified
• Platform MVP complete and tested
• Risk models validated (retrospective n=50,000)
• IoMT integration with 12+ device types
• HIPAA compliance and SOC 2 Type II certified
• Platform MVP complete and tested
• Risk models validated (retrospective n=50,000)
• IoMT integration with 12+ device types
• HIPAA compliance and SOC 2 Type II certified
Join Us in Transforming Cardiac Care
Join Us in Transforming Cardiac Care
We're seeking mission-aligned investors who share our vision of saving lives through AI-powered
cardiovascular medicine. This is your opportunity to be part of a company that will prevent millions of
cardiac events and fundamentally change how we care for heart patients.
We're seeking mission-aligned investors who share our vision of saving lives through AI-powered
cardiovascular medicine. This is your opportunity to be part of a company that will prevent millions of
cardiac events and fundamentally change how we care for heart patients.
Contact Us
Contact Us
Investment Relations: tonywell@cardioailive.com
Investment Relations: tonywell@cardioailive.com
Phone: +1 (614) 967-8728
CFO: Everlyn Ndirangu: neverlyn1@cardioailive.com | +9108827147
CFO: Everlyn Ndirangu: neverlyn1@cardioailive.com | +9108827147
Offices:
Dublin, Ohio | San Francisco, California
Dublin, Ohio | San Francisco, California
Company Website:
www.cardioailive.com
Project Website:
www.cardioailivenet.com
CONFIDENTIAL
CONFIDENTIAL
This document contains confidential and proprietary information. Distribution is limited to qualified investors who have executed a non-disclosure agreement. This document does not constitute an offer to sell or a solicitation of an offer to buy any securities.
This document contains confidential and proprietary information. Distribution is limited to qualified investors who have executed a non-disclosure agreement. This document does not constitute an offer to sell or a solicitation of an offer to buy any securities.
Keep up to date with
Cardio AI
Keep up to date with
Cardio AI
Keep up to date with
Cardio AI
Stay up-to-date with our most recent research
advancements, remarkable scientific findings, and the
brilliant individuals driving them forward. Join our
newsletter today to stay informed!
Stay up-to-date with our most recent research
advancements, remarkable scientific findings, and the
brilliant individuals driving them forward. Join our
newsletter today to stay informed!
Stay up-to-date with our most recent research advancements, remarkable scientific findings, and the brilliant individuals driving them forward. Join our newsletter today to stay informed!
Explore
Explore
Contact Us
Contact Us
Email: support@cardioailive.com
Email: support@cardioailive.com
Address: 6500 Emerald Parkway, Dublin, OH, USA
Address: 6500 Emerald Parkway, Dublin, OH, USA
Our Socials
Our Socials
Our Socials